Diabetes Mellitus, Type 2/complications; Humans; Mass Screening; Myocardial Ischemia/complications/diagnosis
Abstract :
[en] Coronary artery disease is the major cause of mortality of type 2 diabetic subjects. Its early diagnosis to prevent progression and clinical events has intuitive appeal. Somehow, rationale for screening has not been clearly established. Screening should not modify the medical therapy because diabetic subjects have to be treated in a secondary prevention strategy. We have no data from randomized trials concerning a better outcome after revascularization in this specific population. The question how to select the high risk population to be screened has no response by now. SPECT and stress echocardiography seem valuable for screening but not for risk stratification. A large randomized clinical trial is required to confirm the cost-utility ratio of such a screening.
Disciplines :
Cardiovascular & respiratory systems Endocrinology, metabolism & nutrition
Author, co-author :
Wallemacq, Caroline ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
Impact thérapeutique du dépistage de l’ischémie myocardique silencieuse chez le sujet diabétique de type 2
Alternative titles :
[en] Therapeutic impact of screening for myocardial ischemia among asymptomatic type 2 diabetic subjects
Wallemacq C, Van Gaal LF, Scheen AJ. Le coût du diabète de type 2 : résumé de l'étude CODE-2 et analyse de la situation en Belgique. Rev Med Liège 2005;60:278-84.
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes : Estimates of the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases : Executive summary. The task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC) and of the European association for the study of diabetes (EASD). Eur Heart J 2007;28:88-136.
Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32.
American diabetes association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes : 10-11 February 1998, Miami, Florida. Diabetes Care 1998;21:1551-9.
** Puel J, Valensi P, Vanzetto G, et al. Identification de l'ischémie myocardique chez le diabétique : recommandations conjointes SFC/ALFEDIAM. Arch Mal Cœur Vaiss 2004;97:338-54 et Diabetes Metab 2004;30:3S3-18.
Rajagopalan N, Miller TD, Hodge DO, Frye RL, Gibbons RJ. Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol 2005;45:43-9.
* Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006;47:65-71.
Wackers FJ, Young LH, Inzucchi SE, et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects : The DIAD study. Diabetes Care 2004;27:1954-61.
* Bax JJ, Young LH, Frye RL, et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care 2007;30:2729-36.
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003;107:2900-7.
Sorajja P, Chareonthaitawee P, Rajagopalan N, et al. Improved survival in asymptomatic diabetic patients with high-risk SPECT imaging treated with coronary artery bypass grafting. Circulation 2005;112:1311-6.
Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-13.
Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease : Rationale for the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Circulation 2003;107:636-42.
Diamond GA, Kaul S, Shah PK. Screen testing : Cardiovascular prevention in asymptomatic diabetic patients. J Am Coll Cardiol 2007;49:1915-7.
Bax JJ, Inzucchi SE, Bonow RO, et al. Cardiac imaging for risk stratification in diabetes. Diabetes Care 2007;30:1295-304.
Wackers FJ. Diabetes and coronary artery disease : The role of stress myocardial perfusion imaging. Cleve Clin J Med 2005;72:21-33.
Hennessy T, Cood M, Kane G, et al. Evaluation of patients with diabetes mellitus for coronary artery disease using dobutamine stress echocardiography. Coron Artery Dis 1997;8:171-4.
Campisi R, Di Carli M. Assessement of coronary flow reserve and microcirculation : clinical perspective. J Nucl Cardiol 2004;11:3-11.
Kamalesh M, Feigenbaum H, Sawada S. Challenge of identifying patients with diabetes mellitus who are at low risk for coronary events by use of cardiac stress imaging. Am Heart J 2004;147:561-3.
Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 2003;228:826-33.
Wackers FJ, Young LH, Chyun DA, et al. Screening for ischemia in asymptomatic patients with type 2 diabetes : 5-year outcomes in the DIAD study (abstract). Diabetes 2008;57(Suppl. 1):A51.
* Beller GA. Noninvasive screening for coronary atherosclerosis and silent ischemia in asymptomatic type 2 diabetic patients. J Am Coll Cardiol 2007;49:1918-23.
